Re­org com­ing for lit­tle biotech as it shut­ters PhII ra­dioim­munother­a­py tri­al on un­der­whelm­ing da­ta

Af­ter de­cid­ing that its ra­dioim­munother­a­py no longer has a vi­able path to com­mer­cial­iza­tion, Nor­way’s Nordic Nanovec­tor is shut­ting down its lead and on­ly clin­i­cal tri­al …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER